Amarin Corporation
Amarin Corporation
Amarin Corporation is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. The company is best known for its prescription drug, Vascepa, which is derived from fish oil and is used to reduce cardiovascular risk.
History[edit | edit source]
Amarin Corporation was founded in 1993 and is headquartered in Dublin, Ireland. Initially, the company focused on the development of lipid science and the treatment of cardiovascular disease. Over the years, Amarin has shifted its focus to the commercialization of its flagship product, Vascepa.
Products[edit | edit source]
Vascepa[edit | edit source]
Vascepa is Amarin's primary product, an omega-3 fatty acid-based drug designed to lower triglyceride levels in patients with severe hypertriglyceridemia. It has been approved by the Food and Drug Administration (FDA) for use in the United States and has undergone various clinical trials to expand its indications.
Research and Development[edit | edit source]
Amarin Corporation invests heavily in research and development to explore new therapeutic uses for Vascepa and other potential products. The company conducts clinical trials to assess the efficacy and safety of its products in reducing cardiovascular events.
Market and Sales[edit | edit source]
Amarin markets Vascepa primarily in the United States, with efforts to expand its presence in international markets. The company employs a direct sales force and partners with other pharmaceutical companies to promote its products.
Legal and Regulatory Affairs[edit | edit source]
Amarin has been involved in various legal and regulatory matters, including patent disputes and challenges related to the marketing and labeling of Vascepa. The company actively engages with regulatory bodies to ensure compliance and to seek approval for expanded indications of its products.
Corporate Structure[edit | edit source]
Amarin Corporation is publicly traded on the NASDAQ stock exchange under the ticker symbol AMRN. The company is governed by a board of directors and managed by an executive team responsible for strategic decisions and day-to-day operations.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
